The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBraveheart Inv Regulatory News (BRH)

Share Price Information for Braveheart Inv (BRH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.50
Bid: 6.00
Ask: 7.00
Change: 0.00 (0.00%)
Spread: 1.00 (16.667%)
Open: 6.50
High: 6.50
Low: 6.50
Prev. Close: 6.50
BRH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Preliminary Results

21 Jul 2014 07:00

RNS Number : 7969M
Braveheart Investment Group plc
21 July 2014
 



 

21 July 2014

Braveheart Investment Group plc

("Braveheart" or "the Group")

 

Preliminary Results for the year ended 31 March 2014

Key Points

Operational:

· First realisation from Finance Yorkshire Equity Fund;

· Northern Ireland Growth Loan Fund performing in line with expectations;

· Establishment of the Crowdcube Venture Fund (CCVF) and partnership with Crowdcube Ventures;

· Divestment of corporate finance subsidiary Envestors Ltd; and

· Non-executive director Edward Cunningham retired.

Financial:

· Profit from continuing and discontinued operations was £38,000 in H2 (H1: loss of £845,000); 

· Impairment to intangibles for Envestors Ltd was £610,000 in H1 and £95,000 in H2;

· Profit from continuing operations was £38,000 in H2 (H1: loss of £23,000);

· Investment management income remained stable at £2,044,000 (2013: £2,046,000);

· Net unrealised gain on revaluation of portfolio investments of £111,000 (2013: gain of £254,000), giving total portfolio fair value of £3,725,000 (2013: £3,560,000);

· Earnings per share loss of 3.45 pence (2013: profit of 0.30 pence)

· Placed a total of 2,283,855 shares raising £250,000;

· Cash balances of £159,000 (2013: £39,000) with no material borrowings; and

· Net assets per share of 15.51 pence (2013: 19.43 pence).

Events since the year end:

· First realisation from the Lachesis fund; and

· Non-executive director Trevor Brown appointed.

 

Geoffrey C B Thomson Chief Executive said:

"This year has seen good performance and output from our fund management business, the launch of an exciting new fund (Crowdcube Venture Fund) and the divestment of our loss making corporate finance business (Envestors). We have made steady progress with our directly held portfolio and market sentiment for realisations is improving with some weighty valuations for early stage technology company acquisitions being seen in the public markets. 

 

"The financials show a disappointing first half, due in the main to the disposal noted above, but we returned to profitability in the second half. The business is now less volatile and current year's trading is more consistent with what we saw in the second half of last year."

 

Further information:

Braveheart Investment Group plc

Geoffrey Thomson, Chief Executive Tel: +44 1738 587555

gthomson@braveheartgroup.co.uk

 

Sanlam Securities UK Limited (Nominated Adviser and Broker to Braveheart)

Lindsay Mair Tel: +44 20 7628 2200

 

Media Enquiries (Braveheart):

Allerton Communications

Peter Curtain Tel: +44 20 3137 2500

peter.curtain@allertoncomms.co.uk

 

 

CHAIRMAN'S STATEMENT

I am pleased to provide shareholders with my statement which accompanies our financial results for the year ended 31 March 2014.

I would like to begin by thanking all the staff for their diligence and hard work and also recognise the effort and time expended by the non-executive directors. I also extend a warm welcome to Trevor Brown who joined the board as a non-executive director in April 2014.

Envestors Ltd was sold to a management buy-out team on 13 December 2013 and is presented in the financial statements as a discontinued activity. Excluding unrealised portfolio movements, the profit before tax for continuing operations was £1,000 (2013: loss of £120,000). The total profit after tax and amounts attributable to non-controlling interests for continuing operations decreased to £15,000 (2013: £186,000).

Discontinued operations net loss for the year was £823,000 (2013: loss of £119,000).

The profit from continuing and discontinued operations was £38,000 in H2 (H1: loss of £845,000), the improvement in H2 being largely due to the disposal of Envestors Ltd.

The Group will continue to focus on growing the funds under management and achieving realisations from the portfolio to enhance earnings per share.

The economic climate has improved and smaller companies are being encouraged by the Chancellor although I think that further action by the Government should be devoted to research and development, which is always the backbone and future for success.

Jeremy Delmar-Morgan, Chairman

 

 

CHIEF EXECUTIVE OFFICER'S REPORT

I am pleased to report to shareholders for the 12 months ended 31 March 2014.

Overview

This year has seen good performance and output from our fund management business, the launch of an exciting new fund and the divestment of our loss making corporate finance business. We have made steady progress with our directly held portfolio and market sentiment for realisations is improving with some weighty valuations for early stage technology company acquisitions being seen in the public markets.

Growth Loan Fund (GLF)

The GLF is aimed at SMEs in Northern Ireland and typically comprises unsecured term loans of £50k to £1m, usually repayable over three to five years. In 2012, in association with NEL Fund Managers and Clarendon Fund Managers, we established WhiteRock Capital Partners LLP (WhiteRock) to manage the £50m GLF. WhiteRock received its FCA accreditation late in 2013 and took over the management of the GLF as from 1 April 2014. In the interim period, the GLF was run by our subsidiary company, Strathtay Ventures Ltd (see below).

Eighteen months into the investment period, the GLF is now well established in Northern Ireland and we have a good working relationship with local banks, professional advisers and trade organisations. During the year under review, the investment committee approved 43 loans of which 32 were drawn totalling a little of over £10m. In total, 46 loans have been made and we have a good mix of industries in the portfolio.

I am pleased to report that the nine person strong team, led by Paul Miller (CIO), won an industry award at the Insider Northern Ireland Dealmakers Awards on 27 March. This is the third award the team have won and I congratulate them. 

Viking Fund Managers

Andrew Burton's team in the Yorkshire and Humber region had a good year: They achieved the first exit for the £43m Finance Yorkshire Equity Fund (FYEF) selling Rotherham-based S3 ID to Singapore-listed CSE Global. S3 ID was the first investment made by the FYEF and the sale made an aggregate return of £3.4million from an original investment of £1.6million, generating a money multiple of 2.2 on the transaction. 

In the final quarter of the year the team invested a little over £4m in 12 companies and this level of investment is expected to be maintained over the coming months. The portfolio comprised 38 live investments and includes some good businesses which should do well for the region and provide significant returns for shareholders. 

FYEF invests both debt and equity instruments in development capital situations and unit sizes range from £50k to £2m.

Strathtay Ventures

Strathtay, based in Perth, builds and manages the bespoke unquoted portfolios of high net worth individuals with most investments being in maturing technology businesses. These investment typically mirror our own directly-held portfolio (see hereafter).

Strathtay also manages the Lachesis Fund, a £10m seed fund for universities in the East Midlands. This fund is now in wind-up mode and we are in the process of securing two realisations whilst looking at long term disposal options. 

During the period under review, we established a partnership with Crowdcube Ventures Ltd and established the Crowdcube Venture Fund (CCVF). Crowdfunding is now a well established fundraising route for SMEs and we are delighted to be working with one of the UK's most established operators. The CCVF, which is believed to be the first of its kind, enables passive investors to build a portfolio of investments by co-investing in crowd-funded ventures which have been carefully screened by a professional fund manager. We achieved a first close of the fund in April 2014 and we expect to announce a series of investments over the coming months.

Portfolio

A key balance sheet asset of the Group is our investment portfolio. Carolyn Smith, our CIO, is in charge of this portfolio that comprises mainly technology companies which are becoming increasingly mature. We are encouraged by the level of valuations being achieved in the technology sector at present and we continue to work towards optimal realisations which we expect to provide a good return on capital and significant cash resources. 

Envestors

On 13 December 2013 we announced that the Group had completed the sale of Envestors. The sale followed the decision by our Board to sell the business due to the financial performance of the subsidiary. Following aborted offers from trade buyers, we sold the business back to management with the principal element of the consideration being the cancellation of the final Braveheart shares issue due to the three management buy-out participants, as agreed at the time of the Envestors acquisition and detailed in our 2013 Annual Report.

The financial impact of the eight and a half months trading of Envestors is discussed below.

Financial Review

Envestors Ltd was sold to a management buy-out team on 13 December 2013 and is presented in the financial statements as a discontinued activity. 

Excluding unrealised portfolio movements, the profit before tax for continuing operations was £1,000 (2013: loss of £120,000). The total profit after tax and amounts attributable to non-controlling interests for continuing operations decreased to £15,000 (2013: £186,000).

Discontinued operations net loss for the year was £823,000 (2013: loss of £119,000).

The profit from continuing and discontinued operations was £38,000 in H2 (H1: loss of £845,000), the improvement in H2 being largely due to the disposal of Envestors Ltd.

On 25 March 2014 we announced the raising of £250,000 by way of the issue of 2,283,855 ordinary shares at a price of 10.946p per share, being the volume weighted average price over the preceding 60 days (from when the investment was agreed). The cash was raised for working capital purposes.

Board and Personnel

Jeremy Delmar-Morgan took on the role of Non-executive Chairman in April last year and Edward Cunningham stood down as one of our non-executive directors at the AGM in September. 

We are pleased to welcome Trevor Brown to the Board as a non-executive director with the appointment being announced in March 2014.

Strategy

89% of the Group's revenue (excluding portfolio realisations) is now based on contracted fund management services and with this comes good visibility of operational revenue and associated cashflow. From this base the Board is continuing with the strategy of building the investment and fund management areas of the business and we are looking at a number of opportunities involving both additional SME focused funds and funds of a more specialist nature. 

Alongside the building of our fund management business we are concentrating on realising value in our directly-held portfolio in addition to portfolios where we have an ongoing management role. It should be noted that the former of these has a direct impact on our cash position as these investments sit on our balance sheet whereas the latter typically result in a performance fee which is paid in the fullness of time via our fund management contractual arrangements.

Outlook

Over the last year the financial climate has markedly improved and SMEs are now finding it easier to attract funding. This bodes well for our portfolios and with more funding in the SME space we are set to grow our business as the economy continues to improve.

In closing, I would like to thank our staff for all of their hard work, professionalism and commitment over the year. 

Geoffrey Thomson, Chief Executive Officer

 

CHIEF FINANCIAL OFFICER'S REPORT

Income statement

Envestors Ltd was sold to a management buy-out team on 13 December 2013 and is presented in the financial statements as a discontinued activity. 

Fee based revenue for continuing operations is generated by Strathtay Ventures Ltd (SVL) and Viking Fund Managers Ltd (VFM).

The revenue for continuing operations principally comprises investment management fees which remained stable during the year at £2.044 million (2013: £2.046 million).

Finance income was £4,000 (2013: £13,000), the reduction being due to reducing overall balances for outstanding loan notes within the investment portfolio.

As at 31 March 2013, the Group's own investment portfolio of 20 companies was valued at £3.560 million. During the year the Group made an investment of £3,000 (2013: £46,000) into one existing portfolio company by conversion of an existing loan note to equity with the balance of £68,000 (2013: £32,000) being invested in the Northern Ireland Growth Loan Fund (GLF). One portfolio company Convivial London Pubs plc made the decision to sell the assets and an interim distribution of £4,000 was received from the liquidator (2013: no realisations). One existing portfolio company, EctoPharma Ltd, created a new spin-out business, Ryboquin Company Ltd and shares were gifted to the Group as existing shareholders of EctoPharma Ltd. One company repaid loan notes totalling £6,000 (2013: £15,000). At 31 March 2014 the fair value of the investment portfolio of 20 companies was £3.725 million, resulting in an aggregate unrealised revaluation gain of £111,000 (2013: unrealised revaluation gain of £254,000).

The Group's investments are held either by the Company, Strathclyde Innovation Fund LP (SIF), or Caledonia Portfolio Realisations Ltd (CPR). There is an increase in contingent consideration of £97,000 (2013: decrease in contingent consideration of £41,000) payable on future exit values of CPR portfolio companies. 

Total income for continuing operations for the year ended 31 March 2014 including realised gains and unrealised revaluation gains was £2.062 million, a decrease from £2.364 million in 2013.

Employee numbers increased by 1 on average in the year. Employee benefits expense for continuing operations was £1.381 million (2013: £1.432 million). Other operating and finance costs decreased to £0.666 million (2013: £0.746 million). 

Excluding unrealised portfolio movements, the profit before tax for continuing operations was £1,000 (2013: loss of £120,000). The total profit after tax and amounts attributable to non-controlling interests for continuing operations decreased to £15,000 (2013: £186,000), equivalent to a profit per share of 0.08 pence (2013: profit per share of 0.80 pence).

Discontinued operations net loss for the year was £823,000 (2013: loss of £119,000).

The profit from continuing and discontinued operations was £38,000 in H2 (H1: loss of £845,000), the improvement in H2 being largely due to the disposal of Envestors Ltd.

Financial position

Net assets at 31 March 2014 were £4.012 million (2013: £4.520 million), equivalent to 15.51 pence per share (2013: 19.43 pence) the decrease reflecting the new share issue during the financial year.

The Group's net assets include goodwill of £0.752 million (2013: £1.367 million) and intangible assets of £nil (2013: £96,000) the reduction being due to the disposal of Envestors Ltd. The carrying value of goodwill has been reviewed during the year and in light of current projections of future performance the Directors do not believe the assets are impaired.

A new share subscription raised £250,000 from the placing of 2,283,855 shares during the period.

At the year end the Group had cash balances of £159,000 (2013: £39,000). There were no material borrowings. Cash utilisation for continuing operations decreased to £4,000 (2013: £357,000).

A summary analysis of the Group's performance is:

 

2014

2013

 

£'000

£'000

Investment management revenue

2,044

2,046

Finance income

4

13

Income before portfolio movements

2,048

2,059

Change in fair value of investments and movement on contingent consideration

14

306

Total income for continuing operations

2,062

2,365

 

 

 

Employee benefits expense (including share based compensation)

(1,381)

(1,432)

Other operating and finance costs

(666)

(746)

Total costs for continuing operations

(2,047)

(2,178)

 

 

 

Profit/(loss) before tax for continuing operations

15

187

 

 

 

Profit/(loss) after tax and amount

15

187

 

Net results for the year from discontinued operations

(823)

(119)

 

Total (loss) / profit and total comprehensive (loss)/profit for the year.

(808)

68

 

 

 

Opening cash balance

39

424

Increase in portfolio investments

(71)

(46)

Utilised in other activities

(59)

(339)

New share issue

250

-

Closing cash balance

159

39

 

 

 

Net assets

4,012

4,519

 

 

 

Net assets per share

15.51 pence

19.43 pence

 

Aileen Brown, Chief Financial Officer

 

CHIEF INVESTMENT OFFICER'S REPORT

I am pleased to report to shareholders for the year ended 31 March 2014. My specific responsibility is to manage the Group's directly held portfolio and I report principally on that in addition to the Lachesis Fund where I take a lead role. Our CEO has reported elsewhere on other portfolios.

Investment Activity

At the end of the year under review the Group's directly held portfolio of interests comprised 20 companies following the sale of the assets of Convivial London Pubs plc in which the Group and some of its clients had a small holding. Nine of the companies received further funding throughout the year - Traak Systems, Atlas Genetics, Bloxx, mLED, AppShare, EctoPharma, Conjunct, Vascular Flow Technologies and Pyreos. There were no direct investments save for the conversion of fees to equity in the sum of £3,000. Syndicated partners and clients invested £12.6m in aggregate in our portfolio during the year, an increase of £3.2m from the previous year.

Where appropriate, we continue to work with our companies preparing for, and delivering a realisation event - good progress is being made on this front. The timeline to a successful exit is difficult to predict - twelve months ago the M&A market was perceived as largely closed to the size and kind of businesses in our portfolio but we have witnessed some companies being approached as future potential acquisition targets. There is undoubtedly movement in the market with some interesting valuations for technology businesses being made all indicating an apparent renewed level of confidence. In tandem we are seeing some of our portfolio companies transition from prototype production to making product commercially available, and various companies are experiencing a burst in growth in sales and profitability, all helping to solidify a platform from which to seek realisations as part of the strategy for growth. Our portfolio, as can be seen below, is made up of technology-oriented companies most of which are intellectual property asset-rich - this is an important feature in attracting the attention of potential acquirers.

In addition to the owned portfolio, Strathtay Ventures, continues to manage the Lachesis Seed Fund. The limited partners in the Fund are the universities of De Montfort, Leicester, Loughborough, Nottingham, and Nottingham Trent. This fund has been in operation since 2002 and the focus is now on assessing where realisations might be made from the portfolio of 18 spin-out companies. An offer has been accepted to realise the Lachesis stake in one of the companies with completion expected shortly.

Portfolio Performance

During the year the Group's own portfolio showed an unrealised gain before the movement on contingent consideration of £111,083 (2013: unrealised gain of £254,000). The valuations of the portfolio inevitably go up and down year-on-year but the key measurement of success for the Group is the ultimate return on these investments when they are realised. 

Our focus continues to be on developing our key Group asset in the drive to optimise the value of our portfolio and to bring about realisations to help increase shareholder value.

 

Portfolio Company

Description of business

Braveheart Company portfolio

 

AppShare Ltd¹

Web collaboration software design

Atlas Genetics Ltd

Rapid 'point-of-care' molecular diagnostic equipment

Biopta Ltd

Contract research services for drug and tissue measurement

Cascade Technologies Holdings Ltd

Laser-based equipment to detect presence of gases, explosives, etc

Conjunct Ltd

Optical communications components

Design LED Products Ltd

Lighting display technology based on LEDs

Dimensional Imaging Ltd

3D and 4D facial performance systems

EctoPharma Ltd²

Therapeutic healthcare pesticides

mLED Ltd1

Solid-state optical micro-projection systems

NiTech Solutions Ltd

Designs manufacturing solutions for chemical and process industries

Phase Focus Ltd

Lensless microscope technology

Pufferfish Ltd

360° display solutions principally for promotional activities

Pyreos Ltd

Infrared sensor arrays and components for commercial applications

Vascular Flow Technologies Ltd

Cardiovascular medical devices

Traak Systems Ltd

Intelligent self-learning RFID identification and sensor network solutions

Ryboquin Company Ltd²

Commercialisation of patented technologies in human cancer medicine

CPR portfolio

 

Bloxx Ltd

Web filtering and internet filtering software

Leading Software Ltd

IT services

Scalar Technologies Ltd

Thin film measurement

Verbalis Ltd

Language translation software

Ryboquin Company Ltd

Commercialisation of patented technologies in human cancer medicine

EctoPharma Ltd²

Therapeutic healthcare pesticides

¹ Also a Strathclyde Innovation Fund portfolio company

² Also a CPR portfolio company 

 

Carolyn Smith, Chief Investment Officer

 

Consolidated Statement of Comprehensive Income

for the year ended 31 March 2014

 

 

As restated

 

 

2014

2013

 

 

£

£

 

 

 

Revenue

 

2,044,260

2,046,066

Change in fair value of investments

 

111,083

254,063

Movement on contingent consideration

 

(96,877)

51,459

Finance revenue

 

4,027

12,598

Total income

 

2,062,493

2,364,186

 

 

 

Employee benefits expense

 

(1,380,985)

(1,431,655)

Other operating costs

 

(643,045)

(731,329)

Total operating costs

 

(2,024,030)

(2,162,984)

 

 

 

Finance costs

 

(23,035)

(14,795)

 

 

 

Total costs

 

(2,047,065)

(2,177,779)

 

 

 

Profit before tax

 

15,428

186,407

 

 

 

Tax

 

-

-

 

 

 

Profit for the year from continuing operations

 

15,428

186,407

 

 

 

Discontinued operations

 

 

Net results for the year from discontinued operations

 

(803,149)

(118,837)

Loss on disposal of discontinued operations

 

(19,801)

-

Net result for the year from discontinued operations

 

(822,950)

(118,837)

 

 

 

Total (loss)/profit and total comprehensive income for the year

 

(807,522)

67,570

 

 

 

(Loss)/profit attributable to:

 

 

Equity holders of the parent

 

(805,028)

66,607

Non-controlling interest

 

(2,494)

963

 

 

(807,522)

67,570

 

 

 

Basic earnings per share

 

Pence

Pence

- basic and diluted

 

 

From continuing operations

 

0.08

0.83

From discontinued operations

 

(3.53)

(0.53)

From total operations

 

(3.45)

0.30

 

 

 

Consolidated Statement of Financial Position

As at 31 March 2014

 

 

 

2014

2013

 

 

 

£

£

ASSETS

 

 

 

Non-current assets

 

 

 

Goodwill

 

 

751,944

1,367,105

Other intangibles

 

 

-

96,278

Property, plant and equipment

 

 

-

10,332

Investments at fair value through profit or loss

 

 

3,725,132

3,560,417

Investment in limited liability partnership

 

 

5,000

5,000

Other receivables

 

 

-

154,000

 

 

 

4,482,076

5,193,132

 

 

 

 

Current assets

 

 

 

Trade and other receivables

 

 

511,392

461,814

Cash and cash equivalents

 

 

159,434

39,084

 

 

 

670,826

500,898

 

 

 

 

Total assets

 

 

5,152,902

5,694,030

 

 

 

 

LIABILITIES

 

 

 

Current liabilities

 

 

 

Trade and other payables

 

 

(699,621)

(636,302)

Contingent consideration

 

 

(340,721)

(373,694)

Deferred income

 

 

(56,761)

(121,263)

 

 

 

(1,097,103)

(1,131,259)

Non-current liabilities

 

 

 

Borrowings

 

 

(43,392)

(43,392)

 

 

 

(43,392)

(43,392)

 

 

 

 

Total liabilities

 

 

(1,140,495)

(1,174,651)

 

 

 

 

Net assets

 

 

4,012,407

4,519,379

 

 

 

 

EQUITY

 

 

 

Called up share capital

 

 

517,409

465,233

Share premium reserve

 

 

1,457,208

1,252,885

Merger reserve

 

 

523,367

494,936

Retained earnings

 

 

1,514,153

2,303,561

Equity attributable to owners of the Parent

 

 

4,012,137

4,516,615

Non-controlling interest

 

 

270

2,764

Total equity

 

 

4,012,407

4,519,379

 

 

Consolidated Statement of Cash Flows

For the year ended 31 March 2014

 

 

 

As restated

 

 

 

2014

2013

 

 

 

£

£

Operating activities

 

 

 

Profit before tax

 

 

15,428

186,407

Adjustments to reconcile profit before tax to net cash flows from operating activities

 

 

 

Depreciation of property, plant and equipment

 

 

5,338

4,490

Share-based payments expense

 

 

15,620

17,300

Increase in the fair value movements of investments

 

 

(111,083)

(254,063)

Acquisition of subsidiaries 

 

 

-

(294,244)

Loss on disposal of property, plant and equipment

 

 

-

6,973

Interest income

 

 

(4,027)

(12,598)

Increase in trade and other receivables

 

 

(122,076)

(203,929)

Increase in trade and other payables

 

 

196,888

192,845

Cash flow from operating activities

 

 

(3,912)

(356,819)

 

 

 

 

Cash generated from discontinued operations

 

 

(171,052)

(168,970)

Net cash flow from operating activities

 

 

(174,964)

(525,789)

 

 

 

 

Investing activities

 

 

 

Proceeds from sale of subsidiary

 

 

94,919

-

Increase in investments

 

 

(70,725)

(45,689)

Repayment

 

 

17,093

14,990

Investment in limited liability partnership

 

 

-

(5,000)

Interest received

 

 

4,027

12,598

Net cash flow from investing activities

 

 

45,314

(23,101)

 

 

 

 

Financing activities

 

 

 

Proceeds from issue of new shares

 

 

250,000

164,000

Net cash flow from financing activities

 

 

250,000

164,000

 

 

 

 

Net increase/(decrease) in cash and cash equivalents

 

 

120,350

(384,890)

Cash and cash equivalents at the beginning of the year

 

 

39,084

423,974

Cash and cash equivalents at the end of the year

 

 

159,434

39,084

 

 

Consolidated Statement of Changes in Equity

For the year ended 31 March 2014

Attributable to owners of the Parent

Share Capital

 

Shares to be issued

Share Premium

Merger Reserve

Retained Earnings

Total

Non-controlling interest

Total Equity

£

£

£

£

£

£

£

£

Group

At 1 April 2012

385,620

336,000

819,551

431,821

2,214,934

4,187,926

1,801

4,189,727

Issue of new share capital

79,613

(336,000)

433,334

63,115

-

240,062

-

240,062

Share-based payments

-

-

-

-

22,020

22,020

-

22,020

Transactions with owners

79,613

(336,000)

433,334

63,115

22,020

262,082

-

262,082

Profit and total comprehensive income for the year

-

-

-

-

66,607

66,607

963

67,570

At 1 April 2013

465,233

-

1,252,885

494,936

2,303,561

4,516,615

2,764

4,519,379

Issue of new share capital

52,176

-

204,323

28,431

-

284,930

-

284,930

Share-based payments

-

-

-

-

15,620

15,620

-

15,620

Transactions with owners

52,176

-

204,323

28,431

15,620

300,550

-

300,550

Loss and total comprehensive income for the year

-

-

-

-

(805,028)

(805,028)

(2,494)

(807,522)

At 31 March 2014

517,409

-

1,457,208

523,367

1,514,153

4,012,137

270

4,012,407

 

NOTES

1. This preliminary announcement was approved for issue by the Board of Directors on 18 July 2014.

2. Basis of preparation

The financial information set out in this announcement does not constitute statutory financial statements for the years ended 31 March 2014 or 31 March 2013. Statutory accounts for the years ended 31 March 2014 and 31 March 2013 have been reported on by the Independent Auditors.

The Independent Auditors' Reports on the Annual Report and Financial Statements for 2014 and 2013 were unqualified, did not draw attention to any matters by way of emphasis, and did not contain a statement under s.498(2) or s.498(3) of the Companies Act 2006. The directors have reviewed the Group's and the Company's budgets and plans, taking account of reasonably possible changes in trading performance and the level of currently available but undrawn bank facilities, have a reasonable expectation that the Group and the Company have adequate resources to continue in operational existence for the foreseeable future and that it is therefore appropriate to continue to adopt the going concern basis in preparing the financial statements. The accounting policies adopted in this announcement have been consistently applied to all the years presented and are consistent with the policies used in the preparation of the statutory accounts for the period ended 31 March 2013. The statutory financial statements for the year ended 31 March 2013 have been delivered to the Registrar of Companies. The statutory financial statements for the year ended 31 March 2014 will be delivered to the Registrar of Companies following the Company's Annual General Meeting.

3. Tax

No liability to UK corporation tax arose on ordinary activities for the year ended 31 March 2014 or for the year ended 31 March 2013.

 

 

Continuing operations

Continuing operations

 

 

Group

Group

 

 

2014

2013

Reconciliation of total tax:

 

£

£

Profit before tax

 

15,428

186,407

 

 

 

 

Tax at the statutory rate of 20% (2013 : 20%)

 

3,085

37,281

Disallowed expenses

 

(203,437)

(4,678)

Unrealised gain on the fair value movement of investments

 

(22,217)

(50,813)

Increase in unutilised tax losses

 

225,989

17,312

Other adjustments

 

(3,420)

898

Total tax reported in the statement of comprehensive income

 

-

-

 

 

 

Discontinued operations

Discontinued operations

 

 

Group

Group

 

 

2014

2013

Reconciliation of total tax:

 

£

£

Loss before tax

 

(822,950)

(118,837)

 

 

 

 

Tax at the statutory rate of 20% (2013 : 20%)

 

(164,590)

(23,767)

Disallowed expenses

 

-

944

Increase in unutilised tax losses

 

160,102

22,585

Other adjustments

 

4,488

238

Total tax reported in the statement of comprehensive income

 

-

-

 

4. Earnings per share

Basic profit/(loss) per share has been calculated by dividing the loss attributable to equity holders of the parent by the weighted average number of ordinary shares in issue during the year.

The calculations of loss per share are based on the following loss and numbers of shares in issue:

 

 

 

2014

 

 

2013

 

£

£

Profit for the year from continuing operations

17,922

185,444

Loss for the year from discontinued operations

(822,950)

(118,837)

 

 

 

Weighted average number of ordinary shares in issue:

No.

No.

For basic profit/(loss) per ordinary share

23,347,249

22,463,876

Potentially dilutive ordinary shares

-

-

For diluted profit/(loss) per ordinary share

23,347,249

22,463,876

 

5. Goodwill

VFM

Envestors

Neon

Total

£

£

£

£

At 1 April 2012

371,944

615,161

365,810

1,352,915

Movement

-

-

14,190

14,190

At 1 April 2013

371,944

615,161

380,000

1,367,105

Movement

-

(615,161)

-

(615,161)

At 31 March 2014

371,944

-

380,000

751,944

 

The acquisition of Viking Fund Managers (VFM) has been accounted for under IFRS 3. At initial recognition, contingent consideration settled, or to be settled, in shares was fair valued by reference to the Company's share price at the acquisition date.

The acquisition of Envestors has been accounted for under IFRS 3 Revised. At initial recognition, consideration settled, or to be settled, in shares was fair valued by reference to the Company's share price at the acquisition date. Envestors Ltd was sold on 13 December 2013.

The acquisition of Neon has been accounted for under IFRS 3 Revised. During the year ended 2013, the consideration was settled in full. Changes which arose within the measurement period resulted in a revised net asset value for Neon.

At the end of the year, the Group assessed the recoverable amount of the above goodwill associated with each of the VFM and Neon's cash-generating units (both being part of the Group's only operating segment), and determined that goodwill was not impaired. The recoverable amount was assessed by reference to the cash-generating unit's value in use based on internally prepared and approved 3 year cash flow projections and growth based projections for a further 2 years (a reasonable measurement period in the group's line of business) assuming the following growth rates and applying the following discount factors:

Cashflow projections are mainly based on contracted revenues and associated costs, which can therefore be predicted with reasonable certainty and the directors do not consider there to be significant assumptions included within these cash flows.

 

Cash-generating unit

Neon

VFM

2014

2013

2014

2013

Growth rate (average p.a.)

2.5%

-

2.5%

3 - 5%

Discount factor (p.a.)

9-12.5%

9-12.5%

9-12.5%

9-12.5%

These factors are based on past experience and future expectations which the directors consider to be appropriate. Value in use estimates arising from reasonably possible changes to these factors do not indicate impairment.

 

6. Intangible Assets

 

Brand

Database

Total

Group

£

£

£

Cost

 

 

 

At 1 April 2013 and 31 March 2014

66,869

61,500

128,369

 

Accumulated amortisation

At 1 April 2013

16,716

15,375

32,091

Amortisation and impairment

50,153

46,125

96,278

At 31 March 2014

66,869

61,500

128,369

 

Net Book Value

At 31 March 2014

-

-

-

At 31 March 2013

50,153

46,125

96,278

 

Intangible assets acquired on acquisition first arose on the acquisition by Envestors of the business of Envestors LLP, and comprised Envestors' brand and database of high-net-worth investor contacts. The impairment charge relates to the discontinued operations of the Group.

 

7. Investments at Fair Value through Profit or Loss

Level 1

Level 2

Level 3

Equity investments in quoted companies

Equity investments in unquoted companies

Debt investments in unquoted companies

Equity investments in unquoted companies

Debt investments in unquoted companies

Total

Group

£

£

£

£

£

£

At 1 April 2012

-

-

-

3,224,402

51,253

3,275,655

Additions at Cost

-

-

-

13,831

31,858

45,689

Repayments

-

-

-

-

(14,990)

(14,990)

Change in Fair Value

-

-

-

254,063

-

254,063

At 1 April 2013

-

-

-

3,492,296

68,121

3,560,417

Additions at Cost

-

-

-

2,725

68,000

70,725

Repayments

-

-

-

(4,604)

(12,489)

(17,093)

Change in Fair Value

-

-

-

111,083

-

111,083

At 31 March 2014

3,601,500

123,632

3,725,132

 

The Group classifies its investments using a fair value hierarchy. Classification within the hierarchy has been determined on the basis of the lowest level input that is significant to the fair value measurement of the relevant investment as follows:

· Level 1 - valued using quoted prices in active markets for identical assets;

· Level 2 - valued by reference to valuation techniques using observable inputs other than quoted prices included within Level 1; and

· Level 3 - valued by reference to valuation techniques using inputs that are not based on observable market data.

All unquoted investments have been classified as Level 3 within the fair value hierarchy, their respective valuations having been calculated using a number of valuation techniques and assumptions, notwithstanding that the basis of the valuation methodology used most commonly by the Group is 'price of most recent investment'.

 

8. Deferred and Contingent Consideration

Short term contingent consideration of £340,721 is the sum due on future exit values of the Caledonia Portfolio Realisation portfolio. All consideration due to Envestors has been settled in the year.

At the year ended 31 March 2013 short term contingent consideration of £373,694 comprised (i) £129,849 being the fair value of the short term contingent consideration due to Envestors which was due to be satisfied by the issue of 1,207,903 ordinary shares of 2 pence each in the Company, however this was superseded by the disposal of Envestors Ltd, and (ii) £243,845 being the sum due on future exit values of the Caledonia Portfolio Realisation portfolio.

 

9. Post-reporting date events

Trevor Brown was appointed to the Board as a Non-executive Director on 1 April 2014.

 

10. Availability of financial statements

Copies of the full statutory financial statements will be mailed to shareholders no later than 1 September 2014 from which date they will also be available from the Company's offices at Merlin House, Necessity Brae, Perth PH2 0PF and on its website at www. braveheartinvestmentgroup.co.uk

Disclaimer

This Preliminary Announcement contains certain forward-looking statements, which reflect the knowledge of, and information available to, the directors at the date of preparation of this announcement. By their nature, these statements involve risk and uncertainty because they relate to events and depend on circumstances that may or may not occur in the future and there are a number of factors that could cause actual results or developments to differ materially from those expressed or implied by these forward-looking statements.

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR EANXPFALLEFF
Date   Source Headline
29th Apr 20242:07 pmRNSHolding(s) in Company
29th Apr 20241:42 pmRNSBlock admission six monthly return
10th Apr 20247:00 amRNSHolding(s) in Company
27th Mar 202412:03 pmRNSHolding(s) in Company
6th Mar 20247:00 amRNSAcquisition of further interest in Autins Group
4th Mar 202411:48 amRNSInvestment update – Paraytec Limited
4th Mar 20247:00 amRNSCompletion of sale of Phasefocus
9th Jan 202412:00 pmRNSHolding(s) in Company
22nd Dec 20231:30 pmRNSHolding(s) in Company
22nd Dec 20237:00 amRNSPortfolio update - Proposed sale of Phasefocus
15th Dec 202311:41 amRNSInvestment update - Paraytec Limited
15th Dec 202310:16 amRNSReplacement: Half-year Report
14th Dec 20237:00 amRNSHalf-year Report
29th Nov 20237:00 amRNSInvestment update - Paraytec Limited
14th Nov 20239:02 amRNSHolding(s) in Company
17th Oct 20237:00 amRNSInvestment update – Paraytec Limited
10th Oct 202311:15 amRNSHolding(s) in Company
8th Sep 20237:00 amRNSInvestment update – Kirkstall Limited
8th Sep 20237:00 amRNSBlock admission six monthly return
21st Aug 20237:00 amRNSFurther investment in Phasefocus Holdings Limited
28th Jul 20232:25 pmRNSInvestment update on Paraytec Limited
28th Jul 202311:54 amRNSResult of AGM
5th Jul 20237:00 amRNSPosting of annual report and notice of AGM
4th Jul 20237:00 amRNSHolding(s) in Company
3rd Jul 20237:00 amRNSFinal Results for the year ended 31 March 2023
31st May 20237:00 amRNSInvestment update – Phasefocus Holdings Limited
3rd May 20237:00 amRNSUpdate on investments
24th Apr 202310:49 amRNSHolding(s) in Company
27th Mar 20237:00 amRNSGrant of options
13th Mar 20239:34 amRNSHolding(s) in Company
9th Mar 20237:00 amRNSBlock admission six monthly return
10th Feb 20231:26 pmRNSHolding(s) in Company
30th Jan 20234:37 pmRNSHolding(s) in Company
16th Jan 20237:00 amRNSDirector/PDMR Shareholding
10th Jan 20237:00 amRNSOperational update
22nd Dec 20229:14 amRNSHolding(s) in Company
19th Dec 20229:25 amRNSDirector/PDMR Shareholding
19th Dec 20229:11 amRNSAcquisition of interest in Image Scan Holdings plc
13th Dec 20224:37 pmRNSHolding(s) in Company
15th Nov 20223:09 pmRNSHolding(s) in Company
7th Nov 20227:00 amRNSDirector/PDMR Shareholding
28th Oct 20227:00 amRNSHalf-year Report
21st Oct 202210:33 amRNSHolding(s) in Company
20th Oct 20221:59 pmRNSAcquisition of further interest in Autins
5th Oct 20223:15 pmRNSHolding(s) in Company
5th Oct 202212:28 pmRNSAcquisition of further interest in Aukett Swanke
30th Sep 20225:00 pmRNSTotal Voting Rights
20th Sep 20227:00 amRNSPlacing and subscription to raise £750,000
9th Sep 20227:00 amRNSBlock admission six monthly return
6th Sep 20227:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.